Zhen Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhen Wang has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Jun Wan
Department of Cardiology Renmin Hospital of Wuhan University Wuhan China
4 shared publications Huimin Jiang
Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan University, Hubei Key Laboratory of Cardiology, Wuhan 430060, China
3 shared publicationsJianfang Liu
Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan University, Hubei Key Laboratory of Cardiology, Wuhan 430060, China
3 shared publicationsJing Ye
Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan University, Hubei Key Laboratory of Cardiology, Wuhan 430060, China; Department of Cardiology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China
3 shared publicationsJingtang Hu
Department of Cardiology, The General Hospital of Western Theater Command, Chengdu, China
3 shared publicationsMenglong Wang
Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute, Wuhan University, Hubei Key Laboratory of Cardiology, Wuhan 430060, China
3 shared publications
Latest Publications
- Open Access
- 27 August 2026
- Published by Elsevier in SSRN Electronic Journal
Ultrasound-gated dual-drug PLGA nanoparticles co-delivering rapamycin and an NO donor in cardiac allograft rejection
Acute rejection remains a major obstacle to long-term graft survival after heart transplantation. Conventional immunosuppressants such as rapamycin (RAPA) effectively inhibit T-cell proliferation, but their use is limited by systemic toxicity and a lack of microenvironmental precision. In this study, we developed an ultrasound-responsive poly-lactic-co-glycolic acid (PLGA) nanoplatform co-loaded with RAPA and the nitric oxide (NO) donor BNN6 (P-BNN6/RAPA) for hierarchical immune modulation. The nanoparticles exhibited uniform morphology, high encapsulation efficiency, and ultrasound-triggered NO release that accelerated RAPA diffusion. In vitro, ultrasound-activated P-BNN6/RAPA reprogrammed macrophages from a pro-inflammatory M1 to an anti-inflammatory M2 phenotype. In a rat cardiac transplant model, the nanoparticles accumulated in allografts and, upon ultrasound stimulation, promoted localized release of NO and RAPA, modulating macrophage polarization, attenuating inflammatory cytokine production, and extending graft survival. This approach offered a precise and stable strategy for heart transplantation.
- 27 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessUltrasound-gated dual-drug PLGA nanoparticles co-delivering rapamycin and an NO donor in cardiac allograft rejection
Acute rejection remains a major obstacle to long-term graft survival after heart transplantation. Conventional immunosuppressants such as rapamycin (RAPA) effectively inhibit T-cell proliferation, but their use is limited by systemic toxicity and a lack of microenvironmental precision. In this study, we developed an ultrasound-responsive poly-lactic-co-glycolic acid (PLGA) nanoplatform co-loaded with RAPA and the nitric oxide (NO) donor BNN6 (P-BNN6/RAPA) for hierarchical immune modulation. The nanoparticles exhibited uniform morphology, high encapsulation efficiency, and ultrasound-triggered NO release that accelerated RAPA diffusion. In vitro, ultrasound-activated P-BNN6/RAPA reprogrammed macrophages from a pro-inflammatory M1 to an anti-inflammatory M2 phenotype. In a rat cardiac transplant model, the nanoparticles accumulated in allografts and, upon ultrasound stimulation, promoted localized release of NO and RAPA, modulating macrophage polarization, attenuating inflammatory cytokine production, and extending graft survival. This approach offered a precise and stable strategy for heart transplantation.
- Open Access
- 27 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Development and internal evaluation of a composite electrophysiological criterion for the diagnosis of paroxysmal atrial fibrillation
- 27 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessDevelopment and internal evaluation of a composite electrophysiological criterion for the diagnosis of paroxysmal atrial fibrillation
- 27 March 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 178, 116562
Artesunate protects against ischemic stroke through THBS2/CD36/TLR4 pathway
- 27 March 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 178, 116562
Artesunate protects against ischemic stroke through THBS2/CD36/TLR4 pathway
- Open Access
- 7 October 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 31 (37) , 112388
Recent advances in the diagnosis of celiac disease
Celiac disease (CD) is a prevalent immune-mediated disorder triggered by gluten ingestion in genetically susceptible individuals. Primarily affecting the small intestine, CD can also have adverse systemic health effects. However, the majority of affected individuals remain undiagnosed because of asymptomatic or subclinical manifestations. While the diagnostic gold standard remains the combination of positive serum immunoglobulin A antibodies against tissue transglutaminase and villous atrophy on small intestinal biopsy, an evolving understanding of CD pathogenesis has elevated various serum biomarkers to increasingly important complementary diagnostic tools. This editorial aims to outline the scientific merits and potential limitations of serum biomarker assays for CD diagnosis, alongside their established and emerging clinical applications in both initial diagnosis and long-term disease monitoring.
- 7 October 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 31 (37) , 112388
Open AccessRecent advances in the diagnosis of celiac disease
Celiac disease (CD) is a prevalent immune-mediated disorder triggered by gluten ingestion in genetically susceptible individuals. Primarily affecting the small intestine, CD can also have adverse systemic health effects. However, the majority of affected individuals remain undiagnosed because of asymptomatic or subclinical manifestations. While the diagnostic gold standard remains the combination of positive serum immunoglobulin A antibodies against tissue transglutaminase and villous atrophy on small intestinal biopsy, an evolving understanding of CD pathogenesis has elevated various serum biomarkers to increasingly important complementary diagnostic tools. This editorial aims to outline the scientific merits and potential limitations of serum biomarker assays for CD diagnosis, alongside their established and emerging clinical applications in both initial diagnosis and long-term disease monitoring.
- 20 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (3) , 591
Utilizing multimodal imaging for the diagnosis of a rare calcifying fibrous tumour in the right ventricle
- 20 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (3) , 591
Utilizing multimodal imaging for the diagnosis of a rare calcifying fibrous tumour in the right ventricle
- Open Access
- 30 August 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (2) , 1301-1302
In-situ recurrence of cardiac myxoid liposarcoma after surgery
- 30 August 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (2) , 1301-1302
Open AccessIn-situ recurrence of cardiac myxoid liposarcoma after surgery
- Open Access
- 16 June 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (12) , 1270
Left Ventricular Papillary Muscle: Anatomy, Pathophysiology, and Multimodal Evaluation
As an integral part of the mitral valve apparatus, the left ventricle papillary muscle (PM) controls mitral valve closure during systole and participates in the ejection process during left ventricular systole. Mitral regurgitation (MR) is the most immediate and predominant result when the PM is structurally or functionally abnormal. However, dysfunction of the PM is easily underestimated or overlooked in clinical interventions for MR-related diseases. Therefore, adequate recognition of PM dysfunction and PM-derived MR is critical. In this review, we systematically describe the normal anatomical variations in the PM and the pathophysiology of PM dysfunction-related diseases and summarize the commonly used parameters and the advantages and disadvantages of various noninvasive imaging modalities for the structural and functional assessment of the PM.
- 16 June 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (12) , 1270
Open AccessLeft Ventricular Papillary Muscle: Anatomy, Pathophysiology, and Multimodal Evaluation
As an integral part of the mitral valve apparatus, the left ventricle papillary muscle (PM) controls mitral valve closure during systole and participates in the ejection process during left ventricular systole. Mitral regurgitation (MR) is the most immediate and predominant result when the PM is structurally or functionally abnormal. However, dysfunction of the PM is easily underestimated or overlooked in clinical interventions for MR-related diseases. Therefore, adequate recognition of PM dysfunction and PM-derived MR is critical. In this review, we systematically describe the normal anatomical variations in the PM and the pathophysiology of PM dysfunction-related diseases and summarize the commonly used parameters and the advantages and disadvantages of various noninvasive imaging modalities for the structural and functional assessment of the PM.
- Open Access
- 1 March 2023
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. ume 18, 397-407
Prognostic Value of Systemic Immune-Inflammation Index and NT-proBNP in Patients with Acute ST-Elevation Myocardial Infarction
Objective: Our aim was to assess systemic immune-inflammation index (SII) and NT-proBNP value either in singly or in combination to predict acute ST-elevation myocardial infarction (STEMI) patient prognosis. Methods: Analyzed retrospectively the clinical features and laboratory data of STEMI confirmed patients in our hospital from January to December 2020. The levels of SII and NT-proBNP were detected. The Kaplan-Meier approach and Spearman’s rank correlation coefficient were used to construct the overall major adverse cardiac event (MACE) curve. Multivariate Cox regression analysis was applied to detect MACE predictors. In addition, the Delong test and receiver operating characteristic (ROC) curve analyzed each factor performance on its own and composite multivariate index to predict MACEs. Results: The MACE group showed statistically significant differences in SII, NT- proBNP in comparison to the non-MACE group (P=0.003, P < 0.001). Based on Kaplan-Meier analysis, SII and NT-proBNP showed positive correlation with MACE (log-rank P < 0.001). SII and NT-proBNP were independent predicting factors for long-term MACEs in multivariate Cox regression analysis (P < 0.001, HR: 2.952, 95% CI 1.565– 5.566; P < 0.001, HR: 2.112, 95% CI 1.662– 2.683). SII and NT-proBNP exhibited a positive correlation (R = 0.187, P < 0.001) in correlation analysis. According to the ROC statistical analysis, the combination exhibited 78.0% sensitivity and 88.0% specificity in the prediction of MACE. According to the results of the AUC and Delong test, the combined SII and NT-proBNP performed better as a prognostic index than each of the individual factor indexes separately (Z = 2.622, P = 0.009; Z = 3.173, P < 0.001). Conclusion: SII and NT-proBNP were independent indicators of clinical prognosis in acute STEMI patients, and they correlated positively. These factors could be combined to improve clinical prognosis.
- 1 March 2023
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. ume 18, 397-407
Open AccessPrognostic Value of Systemic Immune-Inflammation Index and NT-proBNP in Patients with Acute ST-Elevation Myocardial Infarction
Objective: Our aim was to assess systemic immune-inflammation index (SII) and NT-proBNP value either in singly or in combination to predict acute ST-elevation myocardial infarction (STEMI) patient prognosis. Methods: Analyzed retrospectively the clinical features and laboratory data of STEMI confirmed patients in our hospital from January to December 2020. The levels of SII and NT-proBNP were detected. The Kaplan-Meier approach and Spearman’s rank correlation coefficient were used to construct the overall major adverse cardiac event (MACE) curve. Multivariate Cox regression analysis was applied to detect MACE predictors. In addition, the Delong test and receiver operating characteristic (ROC) curve analyzed each factor performance on its own and composite multivariate index to predict MACEs. Results: The MACE group showed statistically significant differences in SII, NT- proBNP in comparison to the non-MACE group (P=0.003, P < 0.001). Based on Kaplan-Meier analysis, SII and NT-proBNP showed positive correlation with MACE (log-rank P < 0.001). SII and NT-proBNP were independent predicting factors for long-term MACEs in multivariate Cox regression analysis (P < 0.001, HR: 2.952, 95% CI 1.565– 5.566; P < 0.001, HR: 2.112, 95% CI 1.662– 2.683). SII and NT-proBNP exhibited a positive correlation (R = 0.187, P < 0.001) in correlation analysis. According to the ROC statistical analysis, the combination exhibited 78.0% sensitivity and 88.0% specificity in the prediction of MACE. According to the results of the AUC and Delong test, the combined SII and NT-proBNP performed better as a prognostic index than each of the individual factor indexes separately (Z = 2.622, P = 0.009; Z = 3.173, P < 0.001). Conclusion: SII and NT-proBNP were independent indicators of clinical prognosis in acute STEMI patients, and they correlated positively. These factors could be combined to improve clinical prognosis.